Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Mantle-Cell 3Waldenstrom Macroglobulinemia 2Neoplasms 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Indolent Non-Hodgkin Lymphoma 1Hepatitis B, Chronic 1Gastrooesophageal Cancer 1

Interventions

entecavir 2peginterferon alfa-2b 1peginterferon alfa-2a 1ibrutinib 1Tenofovir 1Nucleosides 1Interferons 1Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hepatitis B, Chronic × ibrutinib × Clear all
NCT02991638 2018-04-12

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

The University of Hong Kong

Phase 3 Unknown
62 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Hepatitis B, Chronic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡